Can Merkel cell carcinoma be treated with a cancer vaccine

Can Merkel cell carcinoma be treated with a cancer vaccine

VJOncology

3 years
1,026 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Isaac Brownell, MD, PhD of the National Cancer Institute, Bethesda, MD discusses the virus associated with Merkel cell carcinoma and ongoing research into a potential vaccine for the disease during his attendance at the 2016 World Congress on Cancers of the Skin (WCCS) and the Congress of the European Association of Dermato-Oncology (EADO) in Vienna, Austria. Unlike in other skin cancers, Dr Brownell explains that Merkel cell carcinoma is associated with a virus, which may explain why the immune system is able to target so many of the tumors. Viruses express proteins which are not usually expressed in the body, which gives a natural target for the immune system. Because these tumors are driven by a virus and it is necessary for the viral proteins to be expressed, the tumor needs to figure out a way to protect itself from the immune detection of that viral protein, which may be another reason that checkpoint inhibitors are effective in Merkel cell carcinoma. The virus associated with Merkel cell carcinoma is abundant in the environment and can be found on most peoples skin and does not appear to cause any issues. During cancer, the virus is integrated into the host DNA and the virus proteins become mutated which drives tumor formation. Dr Brownell believes developing a vaccine against this virus would not likely be effective as there is not a strong correlation between infection and tumor formation. However, research into vaccines against the tumor formation are ongoing, with the aim to develop a vaccine specifically for patients with Merkel cell carcinoma, which would augment the immune response.
Up Next Autoplay
Do We Still Need The P-Value? @MDAndersonNews
Do We Still Need The P-Value? @MDAndersonNews
Category: Kidney Cancer
6 Views
kidneycancer 16 hours
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Circulating Tumor DNA (ctDNA) Results in 110 Patients with Advanced Clear Cell Renal Cell Carcinoma
Category: Kidney Cancer
7 Views
kidneycancer 17 hours
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients
Category: Non-Hodgkin Lymphoma
1 Views
Cancer-News 18 hours
Importance of Paradigms for Precision Medicine @sloan_kettering
Importance of Paradigms for Precision Medicine @sloan_kettering
Category: News
0 Views
Memorial Sloan Kettering 18 hours
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Precision Medicine in Epichaperome Cancer Therapy @sloan_kettering
Category: News
1 Views
Memorial Sloan Kettering 19 hours
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Myovant Sciences reports 97% Response rate in Phase 3 HERO Once-Daily Study, Oral Relugolix in Advanced Prostate Cancer Men
Category: Prostate Cancer
7 Views
Cancer-News 20 hours
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Anti–PD-1/PD-L1 Antibody Immunotherapy: Will This Affect Clinicians Today?
Category: Immunotherapy
3 Views
Cleveland Clinic 20 hours
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
POSEIDON Reaps Success for Imfinzi in Non-Small Cell Lung Cancer from AstraZeneca, GlobalData says
Category: Non-Small Cell Lung Cancer
1 Views
Cancer-News 20 hours
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Anti–PD-1/PD-L1 Antibody Immunotherapy Commonly Asked Questions @CleClinicMD
Category: Immunotherapy
2 Views
Cleveland Clinic 21 hours
Response to Anti–PD-1/PD-L1  Antibody Immunotherapy @CleClinicMD
Response to Anti–PD-1/PD-L1 Antibody Immunotherapy @CleClinicMD
Category: Immunotherapy
3 Views
Cleveland Clinic 21 hours